Want to see APM full AI Analyst Report?
Top Page
Aptorum Group
(NASDAQ:APM)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.75
▼(-30.37% Downside)
Action:Reiterated
Date:06/26/26
The score is weighed down primarily by weak financial performance (minimal recent revenue, persistent losses, and continued cash burn) and bearish technical signals (price below key moving averages with negative MACD). Valuation offers limited support because the negative P/E reflects ongoing unprofitability and there is no dividend yield data to provide an income offset.
Positive Factors
Balance Sheet Strength
The balance sheet shows improving leverage and a meaningful equity cushion, which reduces near-term refinancing risk and gives a clinical-stage biotech runway to fund R&D and regulatory milestones without immediate commercial cash flows. This structural buffer supports execution over months.
Negative Factors
Absent Commercial Revenue
Revenue effectively at zero indicates the company lacks commercial products and cannot self-fund development. Over a multi-month horizon this increases dependency on external financing or transaction proceeds, raising dilution and execution risk for clinical programs if capital markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
The balance sheet shows improving leverage and a meaningful equity cushion, which reduces near-term refinancing risk and gives a clinical-stage biotech runway to fund R&D and regulatory milestones without immediate commercial cash flows. This structural buffer supports execution over months.
Read all positive factors
Aptorum Group (APM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.53M
Dividend YieldN/A
Average Volume (3M)113.32K
Price to Earnings (P/E)―
Beta (1Y)1.52
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.79
Shares Outstanding6,346,823
10 Day Avg. Volume164,850
30 Day Avg. Volume113,319
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-4.24
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.61
Enterprise Value/Ebitda-1.47
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.1
Revenue Forecast (FY)$106.80M
Aptorum Group Business Overview & Revenue Model
Company Description
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products incl...
How the Company Makes Money
null...
Aptorum Group Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 431.38K | 1.30M | 1.54M |
| Gross Profit | -255.00K | 0.00 | -255.00K | 10.57K | 80.06K | 81.85K |
| EBITDA | -3.75M | -1.82M | -3.76M | -9.48M | -10.32M | -25.83M |
| Net Income | -4.27M | -1.36M | -4.27M | -2.83M | -9.80M | -25.05M |
Balance Sheet | ||||||
| Total Assets | 16.13M | 18.69M | 16.13M | 20.64M | 20.87M | 21.91M |
| Cash, Cash Equivalents and Short-Term Investments | 874.24K | 3.45M | 874.24K | 2.01M | 1.99M | 8.50M |
| Total Debt | 3.35M | 3.44M | 3.35M | 3.49M | 6.85M | 217.17K |
| Total Liabilities | 4.35M | 4.90M | 4.35M | 5.26M | 13.03M | 4.40M |
| Stockholders Equity | 21.13M | 23.12M | 21.13M | 24.85M | 15.71M | 23.61M |
Cash Flow | ||||||
| Free Cash Flow | -1.19M | -1.84M | -1.19M | -7.73M | -12.51M | -14.79M |
| Operating Cash Flow | -1.19M | -1.84M | -1.19M | -7.72M | -12.32M | -14.65M |
| Investing Cash Flow | 58.62K | 0.00 | 58.62K | 624.77K | 2.44M | 16.51M |
| Financing Cash Flow | 1.43K | 4.41M | 1.43K | 4.09M | 6.63M | 2.78M |
Aptorum Group Technical Analysis
Negative
1.07
Price Trends
0.88
Negative
0.87
Negative
1.13
Negative
Market Momentum
-0.04
Positive
43.22
Neutral
26.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APM, the sentiment is Negative. The current price of 1.07 is above the 20-day moving average (MA) of 0.88, above the 50-day MA of 0.88, and below the 200-day MA of 1.13, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 43.22 is Neutral, neither overbought nor oversold. The STOCH value of 26.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APM.
Aptorum Group Risk Analysis
Aptorum Group disclosed 73 risk factors in its most recent earnings report. Aptorum Group reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aptorum Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $8.03M | -0.33 | -341.23% | ― | ― | 71.83% | |
46 Neutral | $50.11M | -0.14 | -35.91% | ― | ― | 40.89% | |
42 Neutral | $6.53M | -4.18 | -9.02% | ― | ― | ― | |
41 Neutral | $18.81M | -0.14 | 0.02% | ― | ― | -101.45% |
* Healthcare Sector Average
APM
Aptorum Group
0.80
-0.10
-10.89%
IMNN
Imunon
1.91
-8.40
-81.47%
DWTX
Dogwood Therapeutics
1.49
-3.11
-67.61%
AEON
AEON Biopharma
0.72
-0.08
-9.49%
OSRH
OSR Holdings
0.32
-1.03
-76.30%
Aptorum Group Corporate Events
Aptorum Shareholders Clear Path for DiamiR Merger and U.S. Domestication
Jun 10, 2026
On June 9, 2026, Aptorum Group shareholders overwhelmingly approved an all-stock merger with DiamiR Biosciences, along with a suite of related corporate actions including a share consolidation, a redomiciling of Aptorum from the Cayman Islands to ...
Aptorum Files Updated S-4 Amendment as DiamiR Merger Advances
May 14, 2026
Aptorum Group Limited, a Cayman Islands–incorporated biopharmaceutical company based in London, operates as a foreign private issuer in the U.S. and uses SEC registration vehicles such as Forms F-3, S-4 and S-8 to finance and advance its hea...
Aptorum Advances DiamiR Merger with Updated S-4 Filing and March 31 Form 6-K
Apr 1, 2026
On March 31, 2026, Aptorum Group Limited reported via a Form 6-K that it is proceeding with its previously announced merger plan with U.S.-based DiamiR Biosciences Corp., under a July 14, 2025 Merger Agreement that will see a newly formed Delaware...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.